英国多中心回顾性研究评估维布妥昔单抗在移植初治的复发难治性经典型霍奇金淋巴瘤中的疗效
该英国多中心回顾性研究纳入99例移植初治的复发难治性经典型霍奇金淋巴瘤患者,均接受过2线治疗且适合移植但缓解不足。中位无进展生存期5.6个月,中位总生存期37.2个月,总缓解率56%(完全缓解29%,部分缓解27%)。61%的患者达到移植,其中34%在维布妥昔单抗后立即移植,27%在维布妥昔单抗反应不足后经挽救治疗延迟移植。
要点
- 维布妥昔单抗使34%患者直接桥接移植,27%经挽救后延迟移植。
- 移植巩固者无进展生存和总生存优于未移植者(P < 0.001)。
- 39%患者从未达到移植,其无进展生存仅3.0个月。
核心结论
- 维布妥昔单抗是有效的低毒桥接方案,使34%患者立即移植、27%患者延迟移植。
- 39%患者从未达到移植,其无进展生存为3.0个月,提示维布妥昔单抗后不适合移植者预后需改善。
研究设计与样本
- 英国全国多中心回顾性研究,纳入99例移植初治的复发难治性经典型霍奇金淋巴瘤患者。
- 所有患者既往接受过2线治疗,被认为适合移植但缓解不足无法进行移植。
- 中位年龄32岁,多数为结节硬化型、ECOG体能状态0-1分和晚期疾病。
主要发现
- 中位无进展生存期5.6个月,中位总生存期37.2个月。
- 总缓解率56%,其中完全缓解29%、部分缓解27%。
- 61%患者达到移植:34%在维布妥昔单抗后立即移植,27%在维布妥昔单抗反应不足后经挽救治疗延迟移植。
- 移植巩固者无进展生存和总生存优于未移植者(P < 0.001)。
- 39%患者从未达到移植,其无进展生存为3.0个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed. The median age was 32 years. Most had nodular sclerosis subtype, Eastern Cooperative Oncology Group performance status 0-1 and advanced stage disease. The median progression-free survival (PFS) was 5·6 months and median overall survival (OS) was 37·2 months. The overall response rate was 56% (29% complete response; 27% partial response). 61% reached SCT: 34% immediately post-BV and 27% following an inadequate BV response but were salvaged and underwent deferred SCT. Patients consolidated with SCT had a superior PFS and OS to those not receiving SCT (P < 0·001). BV is an effective, non-toxic bridge to immediate SCT in 34% and deferred SCT in 27%. 39% never reached SCT with a PFS of 3·0 months, demonstrating the unmet need to improve outcomes in those unsuitable for SCT post-BV.
引用
- Eyre TA, Phillips EH, Linton KM, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017. PMID: 28857136. doi:10.1111/bjh.14898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。